シンチリマブとチモシンアルファ1の併用療法による多系統免疫関連有害事象の症例報告
Ting Li1, Bao-Liang Wu2, Cai-Long Yu1
1Department of Clinical Pharmacology Hangzhou Xixi Hospital Hangzhou China.
Abstract:
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure. By analyzing the course of treatment and regression, the risks and management strategies of combining immune checkpoint inhibitors (ICIs) with immunomodulators are discussed in the light of the literature. This highlights the need for clinical vigilance against possible immune overactivation triggered by combination therapy.
関連する概念動画
What is the Immune System?
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Data Reporting and Recording
Integration of Synaptic Events
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...


